A science-backed comparison of the two most studied cognitive peptides from Russian pharmaceutical research — anxiolytic GABAergic modulation vs nootropic BDNF/NGF activation.
11 min readSide-by-side profilesShips from WisconsinResearch use only
Research Use Only. Selank and Semax are sold by Evo Peptides for in vitro laboratory research only. Not approved for human or veterinary use. Not medical advice.
Background
Anxiolytic vs Nootropic
Two Cognitive Peptides, Two Research Profiles
Selank and Semax are both synthetic heptapeptides developed by Russian research institutions, both registered as pharmaceuticals in Russia, and both studied extensively for cognitive and neurological applications. The comparison is natural — and important, because their mechanisms are distinct enough that they suit different research programs.
Selank is a tuftsin analogue with a primary anxiolytic profile. Its most characterized mechanisms center on GABAergic system modulation, BDNF upregulation, and IL-6 immunomodulation. Semax is an ACTH 4–7 analogue with a primary nootropic and neuroprotective profile. Its most documented mechanisms center on BDNF and NGF upregulation, dopaminergic enhancement, and broad serotonergic modulation.
Both upregulate BDNF — but the pathway, the behavioral endpoint, and the broader neurotransmitter context differ significantly between them.
Compound Profile
Selank — GABAergic & Anxiolytic
🧠
Selank
TKPRPGP · Tuftsin analogue · 7 amino acids
GABAergicBDNFIL-6Russia registered
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized tuftsin analogue — the PGP tripeptide extension dramatically improves half-life over native tuftsin while preserving and expanding biological activity. It has been registered as a pharmaceutical in Russia for anxiety disorders and is used clinically under the brand name "Selank."
GABAergic system modulationSelank's most distinctively anxiolytic mechanism — enhances GABAergic tone, reducing excitatory/inhibitory imbalance. Distinct from benzodiazepine GABA-A direct agonism — Selank modulates rather than directly activates the receptor
BDNF upregulationBrain-Derived Neurotrophic Factor elevation documented in hippocampal models — shared with Semax but through different primary upstream signaling
IL-6 regulationImmunomodulatory effects via cytokine pathway modulation — relevant to neuroinflammatory research contexts and the tuftsin-origin immune signaling component
Enkephalin degradation inhibitionInhibits enkephalin-degrading enzymes, extending endogenous opioid peptide activity — contributes to anxiolytic and mood-regulatory research profile
Semax was developed at Moscow State University from the ACTH 4–7 fragment, extended with Pro-Gly-Pro to improve stability and CNS penetration. Registered as a pharmaceutical in Russia and Ukraine for ischemic stroke, optic nerve atrophy, and cognitive impairment, it has the most extensive neurological indication profile of any peptide in the cognitive research space.
BDNF and NGF upregulationPrimary and most robustly documented mechanism — critical regulators of neuronal survival, synaptic plasticity, and memory consolidation. Semax produces both neurotrophins; Selank primarily upregulates BDNF
Dopaminergic system enhancementIncreases dopamine turnover and receptor sensitivity in prefrontal and striatal regions — relevant to executive function, working memory, and motivation research
Serotonergic modulationInfluences serotonin system activity — secondary to dopaminergic effects but relevant to mood and cognition research protocols examining monoaminergic pathways
Neuroprotection against ischemic damageOne of Semax's most clinically validated mechanisms — reducing neuronal death in ischemia models, directly behind its stroke application registration in Russia
Both Upregulate BDNF — But Through Different Paths
BDNF (Brain-Derived Neurotrophic Factor) is the most important shared endpoint between Selank and Semax — but the pathway, magnitude, and broader neurotransmitter context differ meaningfully. Semax's BDNF upregulation is its primary, most robustly documented mechanism, occurring through direct neurotrophin synthesis pathways in hippocampal and cortical neurons. Selank's BDNF upregulation occurs alongside GABAergic modulation and is documented as part of its broader anxiolytic-nootropic profile.
This shared endpoint creates a scientifically valid rationale for combined research protocols — particularly for studies examining whether additive BDNF effects emerge from dual-compound designs, or for research programs seeking to dissect anxiolytic (Selank) vs cognitive-enhancement (Semax) aspects of neurotrophin activity.
Combined protocol rationale: Selank covers inhibitory pathway modulation (GABA) and immunomodulation (IL-6); Semax covers excitatory pathway enhancement (dopamine, serotonin) and neuroprotection (NGF). Together they address both sides of the excitatory/inhibitory balance in cognitive function research.
Side-by-Side
Compound Comparison
Parameter
Selank
Semax
Origin
Tuftsin analogue (TKPR + PGP)
ACTH 4–7 fragment + PGP
Developer
Institute of Molecular Genetics, RAS
Moscow State University / RAS
Primary profile
Anxiolytic / immunomodulatory
Nootropic / neuroprotective
GABAergic modulation
✓ Primary mechanism
—
BDNF upregulation
✓
✓ Primary mechanism
NGF upregulation
—
✓
Dopaminergic enhancement
Minor
✓ Documented
Immunomodulation (IL-6)
✓
—
Neuroprotection
Indirect
✓ Ischemia models
Russian pharma registration
✓ Anxiety
✓ Stroke, cognition
Research focus
Anxiety, stress, immune
Cognition, neuroprotection
Protocol Design
Research Considerations
When to Use Selank
Selank is the stronger choice for research programs focused on anxiety mechanisms, GABAergic pharmacology, neuroinflammation, or immunomodulatory cognitive interactions. Its Russian pharmaceutical registration for anxiety disorders provides a degree of translational context rare in the peptide research space, and its IL-6 modulation makes it relevant to research programs examining the neuroinflammatory-cognitive connection.
When to Use Semax
Semax is the stronger choice for research programs focused on cognitive enhancement mechanisms, dopaminergic pharmacology, neuroprotection, or neurotrophin-driven plasticity. Its NGF co-upregulation — absent from Selank — makes it the only compound in this class that simultaneously activates both primary CNS neurotrophins (BDNF and NGF), giving it a distinct profile for neuroplasticity and neuroprotection research.
Combined Protocols
The complementary inhibitory (Selank/GABAergic) and excitatory (Semax/dopaminergic) mechanisms make combined research designs scientifically rational for programs examining the full excitatory/inhibitory balance in cognitive models. Both compounds upregulate BDNF, making combined protocols useful for investigating whether synergistic neurotrophin effects emerge from dual-pathway stimulation.
Frequently Asked
Research Questions
What is the difference between Selank and Semax?▾
Selank is a tuftsin analogue with a primarily anxiolytic profile — acting through GABAergic modulation, BDNF upregulation, and IL-6 immunomodulation. Semax is an ACTH 4–7 analogue with a primarily nootropic profile — acting through BDNF/NGF upregulation, dopaminergic enhancement, and serotonergic modulation. Both upregulate BDNF but through different primary pathways and with distinct behavioral research profiles.
Which is better for anxiety research — Selank or Semax?▾
Selank has a more specifically characterized anxiolytic research profile, with documented GABAergic modulation and Russian pharmaceutical registration for anxiety disorders. Semax has some anxiolytic properties as secondary effects but is primarily researched for cognitive enhancement and neuroprotection. For anxiety-focused research, Selank is the more targeted compound.
Can Selank and Semax be used together in research?▾
Combined protocols are scientifically valid. Selank covers GABAergic modulation and anxiolytic pathways (inhibitory); Semax covers dopaminergic/serotonergic enhancement and BDNF/NGF production (excitatory/neurotrophic). Together they address complementary aspects of cognitive function research without mechanism redundancy.
What is the significance of Russian pharmaceutical registration for both compounds?▾
Both Selank and Semax are registered pharmaceuticals in Russia, which means they have passed regulatory review processes and have clinical application profiles. Semax is registered for ischemic stroke, optic nerve atrophy, and cognitive impairment. Selank is registered for anxiety disorders. This provides translational context for research programs that is absent for most peptide compounds, which remain purely preclinical.
Are Selank and Semax available for research in the USA?▾
Yes. Both are available for in vitro laboratory research from Evo Peptides, a Wisconsin-based supplier. COA-verified, lyophilized, same-day shipping on orders before 3:00 PM CST to all 50 states. Sold strictly for research use — not for human or veterinary consumption.
COA-Verified PurityLyophilized & StableSame-Day by 3:00 PM CSTWisconsin-BasedShips All 50 StatesResearch Use OnlyCOA-Verified PurityLyophilized & StableSame-Day by 3:00 PM CSTWisconsin-BasedShips All 50 StatesResearch Use Only
Research Use Only. All products sold by Evo Peptides are for in vitro research and laboratory use only. Not FDA-approved. Not for human or veterinary consumption. Must be 21+ to purchase.